Pear Therapeutics

Mark Deeg


Mark is VP of Discovery and Translational Research at Pear. He previously served as Chief Medical Officer at Regulus Therapeutics. Prior to that, Mark spent over 10 years at Eli Lilly, where he served in roles of increasing responsibility, the last being the Chief Medical Officer of The Chorus Group, a semi-autonomous early drug development unit within the company. His time at Eli Lilly was preceded by 10 years on faculty at Indiana University.

Mark was elected Fellow of the National Lipid Association in 2011 and serves on the Scientific Committee Advisory Board for WARF Therapeutics. He received his MD and PhD at the University of Minnesota followed by Internal Medicine training at Case Western Reserve University and Endocrinology subspeciality training at the University of Washington.